AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30742122 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 35
Study 30742122 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant PD-1 blockade alone
Number of subjects: 35
Study 30742122 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade
Number of subjects: 35
Study 30742122 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant therapy alone
Number of subjects: 35
Study 28935077 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS implantation
Number of subjects: 505
Study 26611191 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-performed cervical length measurement (CLM) after training
Number of subjects: 65
Study 26611191 — intervention group
Group type: COMPARATOR
Intervention: Obstetrician-performed CLM
Number of subjects: 65
Study 23499440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks (cohort A)
Number of subjects: 316
Study 23499440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg plus peginterferon and ribavirin for 24 weeks (cohort B)
Number of subjects: 316
Study 23499440 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of sofosbuvir plus peginterferon and ribavirin followed by 12 weeks of either sofosbuvir monotherapy or sofosbuvir plus ribavirin (cohort C)
Number of subjects: 316
Study 21194997 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction condition (playing video games during heat-capsaicin pain)
Number of subjects: 28
Study 21194997 — intervention group
Group type: COMPARATOR
Intervention: Pain only condition (heat and capsaicin application)
Number of subjects: 28
Study 19288973 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic FVPD consumption
Number of subjects: 0
Study 19288973 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute FVPD consumption
Number of subjects: 0
Study 19288973 — intervention group
Group type: COMPARATOR
Intervention: Sugar-matched control
Number of subjects: 0
Study 16758944 — intervention group
Group type: EXPERIMENTAL
Intervention: HHD with 6% hydroxyethyl starch (HES) 130/0.4 solution, 15 ml/kg before anesthesia and 33 ml/kg intraoperatively
Number of subjects: 80
Study 16758944 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no preoperative HHD
Number of subjects: 80
Study 16758944 — intervention group
Group type: EXPERIMENTAL
Intervention: HHD group
Number of subjects: 80
Study 15089784 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg twice daily
Number of subjects: 18
Study 15089784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11274311 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent infection by Campylobacter jejuni
Number of subjects: 229
Study 11274311 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent infection by cytomegalovirus
Number of subjects: 229
Study 11274311 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent infection by Epstein-Barr virus
Number of subjects: 229
Study 11274311 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexcitable nerves
Number of subjects: 229
Study 11274311 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 229
Study 9278199 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg once daily)
Number of subjects: 0
Study 9278199 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times daily)
Number of subjects: 0
Study 9278199 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril with Indomethacin
Number of subjects: 0
Study 9278199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8350363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily for 2 or 5 years)
Number of subjects: 2365
Study 8350363 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 2365
Study 8350363 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 2365
Study 3784458 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy overweight subjects
Number of subjects: 639
Study 3784458 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (not specified if overweight or not)
Number of subjects: 639
Study 30613054 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program (60 minutes) and TTM based strategies (10 minutes) for 12 weeks (36 sessions)
Number of subjects: 43
Study 30613054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 43
Study 26951208 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban, with a 50% dose reduction in patients with low body weight (≤60 kg), moderate renal impairment (CLCR ≤50 mL/min), or concomitant P-glycoprotein inhibitors.
Number of subjects: 0
Study 26951208 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban without specified dose reduction.
Number of subjects: 0
Study 24763663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with MRI-detected skull-base invasion classification
Number of subjects: 749
Study 22574572 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-frequency electroacupuncture (EA) combined with herbal-moxa moxibustion (15 cm roll, components include corydalis tuber, astragali radix, myrrh, etc.), applied to Jiaji (EX-B 2) and Ashi-point, once daily for 7 days.
Number of subjects: 37
Study 22574572 — intervention group
Group type: COMPARATOR
Intervention: Brufen (0.3 g, b.i.d.), vitamin B1 (10 mg, t.i.d.), vitamin E (100 mg, b.i.d.)
Number of subjects: 37
Study 22574572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received treatment and assessed using the visual analog scale (VAS) for pain reaction.
Number of subjects: 37
Study 19661237 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible VA-guided regimen after three initial injections of ranibizumab
Number of subjects: 0
Study 19661237 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly and quarterly VA-guided regimens
Number of subjects: 0
Study 16640798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Improvement cluster
Number of subjects: 230
Study 16640798 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening cluster
Number of subjects: 230
Study 16640798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Improvement and Worsening clusters
Number of subjects: 230
Study 16640798 — intervention group
Group type: COMPARATOR
Intervention: Steady or Fluctuating clusters
Number of subjects: 230
Study 15262458 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/d with diet (S-D)
Number of subjects: 299
Study 15262458 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 299
Study 11435511 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in plant sterols (replacing milk fat with vegetable fat)
Number of subjects: 40
Study 11435511 — intervention group
Group type: COMPARATOR
Intervention: Control diet with small amounts of plant sterols
Number of subjects: 40
Study 9151289 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of acetaminophen (oral dose)
Number of subjects: 60
Study 9151289 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine treatment
Number of subjects: 60
Study 9151289 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme inducers (rifampicin or phenytoin)
Number of subjects: 60
Study 8292548 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-worth protective students in achievement situations
Number of subjects: 0
Study 3304479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) alone for 4 months followed by chemotherapy + TAM
Number of subjects: 247
Study 3304479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) + chemotherapy simultaneously
Number of subjects: 247
Study 3304479 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone for 8 months followed by TAM + chemotherapy
Number of subjects: 247
Study 29951915 — intervention group
Group type: EXPERIMENTAL
Intervention: R-training (endurance training with blood flow restriction)
Number of subjects: 10
Study 29951915 — intervention group
Group type: COMPARATOR
Intervention: NR-training (endurance training in free-flow condition)
Number of subjects: 10
Study 29951915 — intervention group
Group type: COMPARATOR
Intervention: Control condition (C)
Number of subjects: 10
Study 26995096 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee, whey protein, inulin, and dextrin (group S)
Number of subjects: 269
Study 26995096 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin-enriched beverage (group I)
Number of subjects: 269
Study 26995096 — intervention group
Group type: COMPARATOR
Intervention: Control beverage - coffee alone (group C)
Number of subjects: 269
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in men
Number of subjects: 1099
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised waist circumference (WC) in men
Number of subjects: 1099
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in women
Number of subjects: 1099
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: Raised waist circumference (WC) in women
Number of subjects: 1099
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in men (comparison between 1990 and 2008/09)
Number of subjects: 1099
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥25 kg/m2 in women (comparison between 1990 and 2008/09)
Number of subjects: 1099
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations with higher BMI in men
Number of subjects: 1099
Study 25221948 — intervention group
Group type: EXPERIMENTAL
Intervention: Associations with higher BMI in women
Number of subjects: 1099
Study 22050362 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured programme (home training programme with ergonomic advice, wrist supports, and/or night bandages)
Number of subjects: 297
Study 22050362 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 297
Study 22050362 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 297
Study 20480132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 26
Study 20480132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 26
Study 20480132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 26
Study 20480132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18759640 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 39
Study 18759640 — intervention group
Group type: COMPARATOR
Intervention: Clozapine (after switching from olanzapine)
Number of subjects: 39
Study 15682246 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health promotion activities
Number of subjects: 4000
Study 15682246 — intervention group
Group type: COMPARATOR
Intervention: Control area (no health promotion activities during the trial)
Number of subjects: 4000
Study 15256232 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of the axillary drain (24 hours postoperatively)
Number of subjects: 247
Study 15256232 — intervention group
Group type: COMPARATOR
Intervention: Keeping the drain in until discharge had decreased to less than 40 ml/24 h
Number of subjects: 247
Study 15256232 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the pectoral fascia
Number of subjects: 247
Study 15256232 — intervention group
Group type: COMPARATOR
Intervention: Removal of the pectoral fascia
Number of subjects: 247
Study 11551574 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol orally
Number of subjects: 9264
Study 11551574 — intervention group
Group type: COMPARATOR
Intervention: 10 IU oxytocin intravenously or intramuscularly
Number of subjects: 9264
Study 9362160 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (IFN α)
Number of subjects: 1554
Study 9362160 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (hydroxyurea or busulfan)
Number of subjects: 1554
Study 8489836 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/ml
Number of subjects: 59
Study 8489836 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 300 mg I/ml
Number of subjects: 59
Study 3320229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 356
Study 3320229 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 356
Study 3320229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (in group with three conceptuses)
Number of subjects: 356
Study 3320229 — intervention group
Group type: COMPARATOR
Intervention: Halothane (in group with three conceptuses)
Number of subjects: 356
Study 3320229 — intervention group
Group type: COMPARATOR
Intervention: Both anesthetic agents
Number of subjects: 356
Study 28834259 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (tumor necrosis factor inhibitor), dosage not specified, duration 24 weeks
Number of subjects: 0
Study 26291335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (20-40 mg/day)
Number of subjects: 395
Study 26291335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 26291335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 395
Study 24206796 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter with information about latent TB and the PPD test
Number of subjects: 293
Study 24206796 — intervention group
Group type: COMPARATOR
Intervention: Regular letter (control group)
Number of subjects: 293
Study 21188521 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 (oral daily dose)
Number of subjects: 27
Study 21188521 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 (intravenous weekly doses)
Number of subjects: 27
Study 18334913 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE epsilon4 and BCHE-K alleles
Number of subjects: 464
Study 18334913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 464
Study 17153647 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX/F mouthrinse
Number of subjects: 24
Study 17153647 — intervention group
Group type: COMPARATOR
Intervention: CHX mouthrinse
Number of subjects: 24
Study 17153647 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 24
Study 14610140 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta 1a (IFN[beta]‐1a)
Number of subjects: 19
Study 14610140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10901114 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butyl acetate at 12 ppm (44 or 56 mg/m3)
Number of subjects: 36
Study 10901114 — intervention group
Group type: EXPERIMENTAL
Intervention: n-butyl acetate at 48 ppm (180 or 228 mg/m3)
Number of subjects: 36
Study 10901114 — intervention group
Group type: EXPERIMENTAL
Intervention: toluene at 12 ppm (44 or 56 mg/m3)
Number of subjects: 36
Study 10901114 — intervention group
Group type: EXPERIMENTAL
Intervention: toluene at 48 ppm (180 or 228 mg/m3)
Number of subjects: 36
Study 10901114 — intervention group
Group type: COMPARATOR
Intervention: Clean air baseline conditions
Number of subjects: 36
Study 10901114 — intervention group
Group type: EXPERIMENTAL
Intervention: Digit symbol test of the Wechsler Adult Intelligence Scale
Number of subjects: 36
Study 10901114 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex reaction-time task
Number of subjects: 36
Study 8929726 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine administered according to a 0, 1.5, 3-month schedule
Number of subjects: 120
Study 8929726 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HB vaccine
Number of subjects: 120
Study 1424851 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 30
Study 1424851 — intervention group
Group type: COMPARATOR
Intervention: Sham training (control group)
Number of subjects: 30
Study 3966617 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health care team approach (physician, nurse practitioner, social worker)
Number of subjects: 0
Study 3966617 — intervention group
Group type: EXPERIMENTAL
Intervention: Home health care team approach
Number of subjects: 0
Study 30206908 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive video tutorials (group B, n=12)
Number of subjects: 24
Study 30206908 — intervention group
Group type: COMPARATOR
Intervention: Standard instructional videos (group A, n=12)
Number of subjects: 24
Study 30206908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 24
Study 30206908 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 24
Study 28940335 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigator intervention
Number of subjects: 61
Study 28940335 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 61
Study 26205801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Desferrioxamine, 40 mg/kg/day, 6 days per week for 6 months
Number of subjects: 120
Study 26205801 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Desferrioxamine, 40 mg/kg/day, 6 days per week 8-12 hours per day for 6 months
Number of subjects: 120
Study 26205801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Deferiprone, 75 mg/kg/day in three divided doses daily for 6 months
Number of subjects: 120
Study 26205801 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Deferasirox, 30 mg/kg/day in single dose on empty stomach daily for 6 months
Number of subjects: 120
Study 22913332 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (≥180 seconds, n = 193)
Number of subjects: 382
Study 22913332 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) (≤10 seconds, n = 189)
Number of subjects: 382
Study 20016927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 26
Study 20016927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19741188 — intervention group
Group type: EXPERIMENTAL
Intervention: high-carbohydrate/high-fiber diet (52% total energy, 28 g/1,000 kcal fiber, low glycemic index 58%)
Number of subjects: 18
Study 19741188 — intervention group
Group type: COMPARATOR
Intervention: low-carbohydrate/high-monounsaturated fat diet (45% carbohydrate, 23% monounsaturated fat)
Number of subjects: 18
Study 17121134 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous MgSO4 infusion (12 grams in 500 ml normal saline daily for 12 days)
Number of subjects: 76
Study 17121134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MgSO4 infusion)
Number of subjects: 76
Study 17121134 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 infusion
Number of subjects: 76
Study 15562907 — intervention group
Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD) alone
Number of subjects: 40
Study 15562907 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) + demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 40
Study 11329798 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin (Visudyne) used in conjunction with laser activation (photodynamic therapy) for AMD treatment
Number of subjects: 0
Study 9158305 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel (Prepidil) 0.5 mg in 2.5 ml of triacetin gel
Number of subjects: 185
Study 9158305 — intervention group
Group type: COMPARATOR
Intervention: Hygroscopic mechanical dilators (Dilapan) - up to 4 dilators placed in the endocervical canal
Number of subjects: 185
Study 7962672 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nimodipine orally
Number of subjects: 12
Study 7962672 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/kg tirilazad mesylate as a 10‐minute intravenous infusion
Number of subjects: 12
Study 7962672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nimodipine and tirilazad mesylate
Number of subjects: 12
Study 3609067 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 10 mg dihydroergosine
Number of subjects: 8
Study 3609067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose of 0.75 mg dihydroergosine
Number of subjects: 8
Study 30615075 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 30615075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29415825 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (1 g daily)
Number of subjects: 120
Study 29415825 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g daily)
Number of subjects: 120
Study 29415825 — intervention group
Group type: COMPARATOR
Intervention: Control (1 g cellulose daily)
Number of subjects: 120
Study 26171380 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning aerobic exercises and medicine
Number of subjects: 45
Study 26171380 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon aerobic exercises and medicine
Number of subjects: 45
Study 26171380 — intervention group
Group type: COMPARATOR
Intervention: Medicine only
Number of subjects: 45
Study 23649920 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH(2)O (PEEP group)
Number of subjects: 40
Study 23649920 — intervention group
Group type: COMPARATOR
Intervention: Zero positive end‐expiratory pressure (ZEEP group)
Number of subjects: 40
Study 21812891 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04603629 (70 mg)
Number of subjects: 71
Study 21812891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 19499866 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 300
Study 19499866 — intervention group
Group type: COMPARATOR
Intervention: Control (Fentanyl and Propofol)
Number of subjects: 300
Study 16623961 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-repeat allele of the dopamine transporter (DAT1)
Number of subjects: 0
Study 16623961 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-repeat allele of the dopamine transporter (DAT1) in depressed patients aged >= 35 years
Number of subjects: 0
Study 15338802 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 519
Study 15338802 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium
Number of subjects: 519